Revised criteria for diagnosis of NIFTP reveals a better correlation with tumor biological behavior.
The recent reclassification of a follicular variant of papillary thyroid carcinoma (FVPTC) subset as noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) aims to avoid overtreatment of patients with an indolent lesion. The diagnosis of NIFTP has recently been revisited using more rigid criteria. This study presents histological and molecular findings and a long clinical follow up of 94 of FVPTC, 40 cases of follicular adenoma (FTA) and 22 cases of follicular carcinoma (FTC) that were classified before the advent of the NIFTP classification. BRAF V600E mutation was found in EFVPT samples. Slides were reviewed using these rigid criteria and analysis of numerous sections of paraffin blocks and reclassified as 7 NIFTPs, 2 encapsulated noninvasive FVPTC (EFVPTCs), 29 infiltrative FVPTC (IFVPTCs), 57 invasive EFVPTC (I-EFVPTCs), 39 FTA and 22 FTC. Remarkably, EFVPTC and NIFTP patients were all free of disease at the end of follow up and showed no BRAF mutation. Only one NIFTP sample harbored mutations, an NRAS Q61R. Nonetheless, NRAS mutation was also found in I-EFVPTC. PAX8/PPARG fusion was found in I-EFVPTCs and FTC. Although additional studies are needed to define a specific molecular profile to aid in the diagnosis of lesions with borderline morphological characteristics, we confirmed that the BRAF V600E mutation is an important tool to exclude the diagnosis of NIFTP. We also show that rigorous histopathological criteria should be strongly followed to avoid missing lesions in which more aggressive behavior is present, mainly via the analysis of capsule or vascular invasion and the presence of papillary structures.